NCT06458712招募中1 期
Phase Ia/Ib Open Label, Multi-Centre Dose Escalation Study With Expansion Cohorts to Assess the Safety, Tolerability, and Activity of DSB2455 as Monotherapy in Participants With Advanced Malignancies
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 入组人数
- 180
- 试验地点
- 32
- 主要终点
- Number of patients exhibiting reduction in tumor size.
研究概览
简要总结
Open label, multi-centre, Phase Ia/b adaptive design study with an initial 2-stage Dose Escalation Phase followed by a Dose Expansion Phase.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Sequential
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •The participant (or legally acceptable representative, if applicable) provides written informed consent for the study.
- •Aged ≥18 years of age on the day of signing the informed consent.
- •Histologically confirmed diagnosis of locally advanced and/or metastatic breast cancer, prostate cancer (mCRPC), ovarian cancer, or pancreatic ductal adenocarcinoma (PDAC) with confirmed gene alterations/ mutations as defined in the protocol
- •Has received prior cancer treatment as outlined in the protocol
- •Has measurable disease per RECIST v1.1, or non-measurable disease as defined in the protocol.
- •ECOG performance status of 0 to
- •Life expectancy >12 weeks.
- •Adequate organ function as defined in the protocol.
- •Willing and able to comply with scheduled visits (including follow-up visits), and protocol procedures.
- •Willing and able to undergo imaging procedures as per protocol.
- •Willing to provide blood samples for correlative research purposes.
- •Able to swallow oral medication as an intact dosage form.
- •Prior intervention with an approved non-selective PARP inhibitor is permitted in Dose Escalation only.
- •Has received prior cancer treatment as outlined in the protocol, dependent on disease type.
- •Known asymptomatic or symptomatic brain metastasis, as confirmed by an MRI brain scan, from a primary tumour and meeting the eligibility for the disease types noted above (Dose Expansion only, specific Cohort).
排除标准
- •Myelodysplastic syndrome (MDS), acute myeloid leukaemia (AML) or features suggestive of MDS/AML.
- •Has received a prior PARP1-selective inhibitor.
- •Has received prior systemic anti-cancer therapy including investigational agents or device within 2 or 4 weeks prior to study intervention, dependent on the treatment.
- •Received prior radiotherapy within 2 weeks of the start of study intervention or has a history of radiation pneumonitis.
- •Diagnosis of immunodeficiency or receiving chronic systemic steroid therapy (exceeding 10 mg daily of prednisone equivalent) or any other form of immunosuppressive therapy within 7 days prior to the first dose of study drug.
- •Has received a live or live-attenuated vaccine within 30 days prior to the first dose of study intervention. Note: administration of killed vaccines are allowed.
- •Has had an allogeneic tissue/solid organ transplant.
- •Has an active autoimmune disease that has required systemic intervention in the past 2 years (i.e., with use of disease modifying agents, corticosteroids or immunosuppressive drugs).
- •History of (non-infectious) pneumonitis/interstitial lung disease that required steroids or has current pneumonitis/interstitial lung disease.
- •Refractory nausea and vomiting, impairment of gastrointestinal (GI) function or GI disease that may significantly alter the absorption of study drugs.
- •Undergone major surgery, open biopsy or significant traumatic injury ≤28 days prior to starting study intervention.
- •Has an active infection requiring systemic therapy or an uncontrolled concurrent illness.
- •Known history of human immunodeficiency virus (HIV) infection. No HIV testing is required unless mandated by the local health authority.
- •Known history of Hepatitis B or known active Hepatitis C virus (HCV)
- •Cirrhosis of the liver.
- •Clinically significant pulmonary illness.
- •Impaired cardiac function or clinically significant cardiac disease.
- •Participants with a healing, serious or open wound, ulcer, or bone fracture within 28 days prior to first dose of study intervention.
- •History or current evidence of any condition, therapy, or laboratory abnormality, or other circumstance that might confound the results of the study or interfere with the participants involvement for the full duration of the study.
- •A WOCBP who has a positive urine pregnancy test (within 72 hours) prior to starting the study intervention. If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required.
- •Has a known psychiatric or substance abuse disorder that would interfere with the participant's ability to cooperate with the requirements of the study.
- •Weight loss of >5% in the 8-week period prior to starting study intervention.
- •Known allergy or hypersensitivity to any of the formulation components of DSB
- •Has received radiation therapy to the lung that is >30Gy within 6 months of the first dose of study intervention.
- •Other disease-specific criteria as outlined in the protocol.
研究组 & 干预措施
DSB2455 Dose Escalation & Expansion
Experimental
DSB2455 Dose Escalation & Expansion
干预措施: DSB2455 (Drug)
结局指标
主要结局
Number of patients exhibiting reduction in tumor size.
时间窗: Through study completion, an average of 1 year
Objective Response Rate (ORR)
Number of patients demonstrating dose limiting toxicities and SAEs
时间窗: Through study completion, an average of 1 year
Number of patients demonstrating dose limiting toxicities and SAEs
次要结局
未报告次要终点
研究者
研究点 (32)
Loading locations...
相似试验
终止
1 期
APG-1387 Plus Chemotherapy in Advanced Pancreatic AdenocarcinomaAdvanced Pancreatic CancerNCT04643405Ascentage Pharma Group Inc.21
终止
1 期
GW572016 With Docetaxel and Trastuzumab for the Treatment Of Untreated ErbB2 Over-Expressing Metastatic Breast CancerNeoplasms, BreastNCT00251433Novartis Pharmaceuticals53
已完成
1 期
Evaluate Safety, Tolerability, Pharmacokinetics and Anti-tumor Activity of AZD3759Non Small Cell Lung CancerNCT03360929LYZZ Alpha Holding Ltd15
招募中
1 期
A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab MonotherapyAdvanced CancerAdvanced Solid TumorMetastasisMSI-HighMismatch Repair DeficiencyMelanomaPleural MesotheliomaHepatocellular CancerRenal Cell CancerKidney CancerNon Small Cell Lung CancerAnaplastic Lymphoma Kinase Genomic Tumor AberrationsALK Genomic Tumor AberrationsSkin CancerColorectal CancerHepatocellular CarcinomaRenal Cell CarcinomaNSCLCNCT063623697 Hills Pharma, LLC126
已完成
1 期
A Study of NBF-006 in Non-Small Cell Lung, Pancreatic, or Colorectal CancerColorectal CancerPancreatic CancerNon-Small Cell Lung CancerNCT03819387Nitto BioPharma, Inc.49